FIG 6.

SR59230A, a selective β3-AR antagonist, suppresses VEGF-A-induced lipolysis in sWAT. (A) cAMP levels in sWAT of VEGF Tg mice and their littermate controls after HFD-Dox feeding, with or without SR59230A treatment, for 7 days (n = 4 for control group and n = 5 for VEGF Tg group; Student's t test, *, P < 0.05). (B) IHC staining with anti-phospho-PKA substrate antibody in the sWAT of VEGF Tg mice and their littermate controls after HFD-Dox feeding, with or without SR59230A (SR) treatment, for 7 days (scale bar, 20 μm). (C) MRI analysis of fat mass in VEGF Tg mice and their littermate controls after HFD-Dox feeding, with or without SR59230A treatment, for 7 days. Fat mass was normalized with total body mass (n = 6 per group; Student's t test, *, P < 0.05; **, P < 0.01). (D) H&E staining of sWAT from VEGF Tg mice and their littermate controls after HFD-Dox feeding, with or without SR59230A treatment, for 7 days (scale bar, 50 μm). (E) qPCR analysis of lipolytic genes, namely, Atgl and Hsl, in sWAT of VEGF Tg mice and their littermate controls after HFD-Dox feeding, with or without SR59230A treatment, for 7 days (n = 5 per group; Student's t test, *, P < 0.05). (F and G) Western blotting and quantitative measurement of band density on the Western blots by ImageJ software for phosphorylated HSL at serine 563/660 as well as total HSL levels in sWAT of VEGF Tg mice and their littermate controls after HFD-Dox feeding, with or without SR59230A treatment, for 7 days. Results were normalized with β-actin (n = 3 per group; Student's t test, *, P < 0.05; ***, P < 0.001). (H) Glycerol levels in sWAT of VEGF Tg mice and their littermate controls after HFD-Dox feeding, with or without SR59230A treatment, for 7 days (n = 4 for control group and n = 5 for VEGF Tg group; Student's t test, *, P < 0.05).